Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04599062 · ClinicalTrials.gov registry record · Phase 1
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
A Phase 1 study of Soft Tissue Sarcoma, sponsored by John Rieth.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT04599062 is a Phase 1 study of Soft Tissue Sarcoma that is active but no longer recruiting, run by John Rieth. The registered enrollment target is 8 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04599062, a Phase 1 study of Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by John Rieth.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.
Conditions Studied
Interventions
- RADIATION Radiotherapy
- DRUG Talimogene Laherparepvec
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2028-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04599062
The ClinicalTrials.gov registry entry for NCT04599062 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (90% lower). The listed sponsor is John Rieth, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Radiotherapy is the first listed.
NCT04599062 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04599062 about?
NCT04599062 is a clinical study titled "TVEC and Preop Radiation for Sarcoma (8 ml Dose)". The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.
What is the current status of trial NCT04599062?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-09-10. Estimated completion is 2028-02-16.
What conditions does trial NCT04599062 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT04599062?
The interventions under investigation include: Radiotherapy (RADIATION), Talimogene Laherparepvec (DRUG).
Who is sponsoring clinical trial NCT04599062?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04599062 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.